Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dextromethorphan HBr Clear all
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Cortical Metrics in Intervention Trials With Autism Spectrum Disorders

NCT02212275
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Dextromethophan
Drug
Lead sponsor
Duke University
Other
Eligibility
8 Years to 12 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

NCT03415243
View directory record Official record
Conditions
Common Cold
Interventions
Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1

NCT00000352
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Dextromethorphan
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 26, 2026, 4:42 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

NCT07593222
View directory record Official record
Conditions
Major Depression, Healthy Participants
Interventions
Sham iTBS, TMS, D-cycloserine, Dextromethophan, Placebo
Device · Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Dextromethorphan to Treat Patients With Voice Spasms

NCT00055549
View directory record Official record
Conditions
Voice Disorders
Interventions
Dextromethorphan, Lorazepam
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial

NCT01435798
View directory record Official record
Conditions
Central Neuropathic Pain, Allodynia, Spinal Cord Injury
Interventions
Dextromethorphan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 26, 2026, 4:42 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion

NCT05976646
View directory record Official record
Conditions
Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
Interventions
Placebo, Auvelity
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of CT1812 in Healthy Volunteers

NCT03716427
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CT1812, tolbutamide, dextromethorphan, Omeprazole, midazolam
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

NCT01001299
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Drug cocktail, RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

NCT01218620
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin, Midazolam Hydrochloride, Omeprazole, Tolbutamide, Dextromethorphan Hydrobromide, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 4 Interventional Results available

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

NCT01799941
View directory record Official record
Conditions
Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
Interventions
Nuedexta (DM 20 mg/Q 10 mg)
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

NCT02176018
View directory record Official record
Conditions
Episodic Migraine
Interventions
Dextromethorphan and quinidine, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Dextromethorphan Versus Placebo for Neuropathic Pain

NCT00001344
View directory record Official record
Conditions
Diabetic Neuropathies, Herpes Zoster, Neuralgia
Interventions
dextromethorphan
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

NCT02688088
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Drug Cocktail, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

NCT01324232
View directory record Official record
Conditions
Central Neuropathic Pain, Multiple Sclerosis
Interventions
AVP-923-45, AVP-923-30, AVP-923-20, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

NCT02434861
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

NCT00021697
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
17
States / cities
Loma Linda, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab)
Drug · Other · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

NCT00741468
View directory record Official record
Conditions
Drug Interactions
Interventions
Proellex, CYP1A2 probe, CYP2C9 probe, CYP2C19 probe, CYP2D6 probe, CYP3A4 probe
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 4 Interventional Results available

Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo

NCT02062710
View directory record Official record
Conditions
Cough Reflex Sensitivity
Interventions
diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo, dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 26, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

NCT00056524
View directory record Official record
Conditions
Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
39
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 26, 2026, 4:42 AM EDT
Terminated Not applicable Interventional

A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity

NCT00176553
View directory record Official record
Conditions
Neurotoxicity Syndromes
Interventions
Dextromethorphan
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
2 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 26, 2026, 4:42 AM EDT